SCHEMBL860772

SCHEMBL860772

CC(C)Nc1ccn2ncc(/C=C3/NC(=O)NC3=O)c2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 2/20 0.37
KDM4E B2RXH2 7/20 0.36
MAPT P10636 4/20 0.36
GAA P10253 3/20 0.36
HPGD P15428 4/20 0.35
ALDH1A1 P00352 4/20 0.35
PKM P14618 1/20 0.35
LMNA P02545 3/20 0.35
CSNK2B P67870 2/20 0.35
RAB9A P51151 2/20 0.34
CGAS Q8N884 1/20 0.34
NCOA1 Q15788 1/20 0.34
NCOA3 Q9Y6Q9 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
NTRK1 P04629 2/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12979184 1.00 MEN1 (0.38) MEN1KMT2APOLBKDM4EMAPT
SCHEMBL860773 1.00 MEN1 (0.38) MEN1KMT2APOLBKDM4EMAPT
SCHEMBL12979114 0.86 MEN1 (0.36) MEN1KMT2APOLBKDM4EMAPT
SCHEMBL862082 0.86 MEN1 (0.36) MEN1KMT2APOLBKDM4EMAPT
SCHEMBL862081 0.86 MEN1 (0.36) MEN1KMT2APOLBKDM4EMAPT
SCHEMBL860934 0.81 FYN (0.43) MEN1KMT2APOLBNCOA1NCOA3
SCHEMBL13020866 0.81 FYN (0.43) MEN1KMT2APOLBNCOA1NCOA3
SCHEMBL860933 0.81 FYN (0.43) MEN1KMT2APOLBNCOA1NCOA3
SCHEMBL3483134 0.81 PIM1 (0.40) KDM4EMAPTHPGDALDH1A1PKM
SCHEMBL12979217 0.81 PIM1 (0.40) KDM4EMAPTHPGDALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
EP-2432473-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS Cylene Pharmaceuticals, Inc. (US) 2012-03-28 EP disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010135581-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM1, PIM2, PIM3 MEN1 3936/4885KMT2A 1758/4885POLB 1495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.